Advertisement

Drugs

, Volume 78, Issue 17, pp 1855–1855 | Cite as

Correction to: Elagolix: First Global Approval

  • Yvette N. LambEmail author
Open Access
Correction
  • 373 Downloads

1 Correction to: Drugs (2018) 78(14):1501–1508  https://doi.org/10.1007/s40265-018-0977-4

The article Elagolix: First Global Approval, written by Yvette N. Lamb, was originally published Online First without open access. After publication in volume 78, issue 14, pages 1501–1508 AbbVie Inc., requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by AbbVie Inc. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The original article has been corrected.

Notes

Open Access

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Copyright information

© Springer Nature 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations